Andilab, Ruffamae .

HRN: 27-33-83  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/17/2025
CEFUROXIME 500MG (TAB)
06/17/2025
06/23/2025
ORAL
500mg
BID
Sp NSVD With RMLE
Pending Pharmacy Acceptance 

 Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: